Dataset Information


Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity

ABSTRACT: Transcriptional profiling of peripheral blood mononuclear cells (PBMCs) from 30 subjects collected at day 0, day 1 and day 3 post yellow fever (YF) vaccination. Each patient sample is performed in duplicate to reduce the chance of error. Briefly, the project investigates how cross-reactive JE antibodies that are generated from prior vaccination can influence YF live-attenuated vaccine (LAV). The groups are hence segregated based on the YF antibody titers after 1 month vaccination. Group 4 refers to the control group where individuals received only the YF LAV. Enhancing group refers to the treatment group (given JE followed by YF vaccine), where individuals had YF antibody titers higher than 99% confidence interval of the YF antibody titers of the control group. Non-enhancing group, on the other hand, refers to the treatment group where individuals had YF antibody titers within or lower 99% confidence interval of the control group. Our present study provides evidence that enhancing levels of cross-reactive antibodies from prior Japanese encephalitis (JE) vaccination can improve subsequent YF immunogenicity. These microarray results indicate the genes and gene signatures that are associated with the differences in YF immunogenicity.

ORGANISM(S): Homo sapiens  

SUBMITTER: Kuan Rong Chan  

PROVIDER: E-MTAB-4669 | ArrayExpress | 2017-09-05


Similar Datasets

2008-11-14 | GSE13587 | GEO
| GSE86331 | GEO
2008-11-22 | E-GEOD-13587 | ArrayExpress
2008-11-23 | GSE13485 | GEO
2008-11-22 | E-GEOD-13485 | ArrayExpress
2014-04-10 | E-GEOD-47353 | ArrayExpress
| GSE108901 | GEO
| GSE26347 | GEO
2014-03-31 | E-GEOD-52005 | ArrayExpress
| GSE100745 | GEO